Federal grant · National Institutes of Health

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Status
Open
Posted
Dec 4, 2024
Closes
Nov 5, 2027
Est. total funding
—
Award range
— – $1.5M
Expected awards
—
Opportunity number
PAR-25-297
Who can apply

Eligible applicants

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

About this grant

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

Instrument
Cooperative agreement
Activity
Health
Assistance listings
93.866
Cost sharing
Not required
Last updated
Dec 4, 2024

From Grants.gov's public daily extract of Oct 25, 2026. Agency contacts, full eligibility and application packages are on Grants.gov; always confirm deadlines there before applying.

Find more grants your organization can apply for — free →
Search every open federal grant by applicant type, agency and activity. No credit card.
Get free alerts

More open grants from Department of Health and Human Services · All open federal grants